84 related articles for article (PubMed ID: 1518307)
1. Interleukin-2 induction of lymphokine-activated killer activity in the peripheral blood of an acute lymphoblastic leukaemia patient--case study.
Dickinson AM; Lennard AL; Cartner R; Proctor SJ
Leukemia; 1992 Sep; 6(9):957-60. PubMed ID: 1518307
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
[TBL] [Abstract][Full Text] [Related]
3. Generation of LAK cells in vitro in patients with acute leukemia.
Parrado A; Rodriguez-Fernandez JM; Casares S; Noguerol P; Plaza E; Parody R; Espigado I; de Blas JM; Garcia-Solis D
Leukemia; 1993 Sep; 7(9):1344-8. PubMed ID: 8371585
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patients.
Messina C; Zambello R; Rossetti F; Gazzola MV; Varotto S; Destro R; Basso G; Semenzato G; Zanesco L
Bone Marrow Transplant; 1996 May; 17(5):729-35. PubMed ID: 8733689
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer cytotoxicity against leukaemic blast cells.
Tratkiewicz JA; Szer J; Boyd RL
Clin Exp Immunol; 1990 Apr; 80(1):94-9. PubMed ID: 2323104
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
8. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance.
Archimbaud E; Bailly M; Doré JF
Br J Haematol; 1991 Mar; 77(3):328-34. PubMed ID: 2012757
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.
Foa R; Guarini A; Gillio Tos A; Cardona S; Fierro MT; Meloni G; Tosti S; Mandelli F; Gavosto F
Cancer Res; 1991 Feb; 51(3):964-8. PubMed ID: 1988139
[TBL] [Abstract][Full Text] [Related]
10. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study.
Meloni G; Foà R; Tosti S; Vignetti M; Mancini F; Guarini A; Marchis D; Gavosto F; Mandelli F
Leukemia; 1992 Aug; 6(8):780-5. PubMed ID: 1640729
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.
Maraninchi D; Vey N; Viens P; Stoppa AM; Archimbaud E; Attal M; Baume D; Bouabdallah R; Demeoq F; Fleury J; Michallet M; Olive D; Reiffers J; Sainty D; Tabilio A; Tiberghien P; Brandely M; Hercend T; Blaise D
Leuk Lymphoma; 1998 Oct; 31(3-4):343-9. PubMed ID: 9869198
[TBL] [Abstract][Full Text] [Related]
12. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer.
Urba WJ; Steis RG; Longo DL; Kopp WC; Maluish AE; Marcon L; Nelson DL; Stevenson HC; Clark JW
Cancer Res; 1990 Jan; 50(1):185-92. PubMed ID: 2293554
[TBL] [Abstract][Full Text] [Related]
15. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission.
Adler A; Albo V; Blatt J; Whiteside TL; Herberman RB
Blood; 1989 Oct; 74(5):1690-7. PubMed ID: 2790193
[TBL] [Abstract][Full Text] [Related]
17. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.
Hermann GG; Geertsen PF; von der Maase H; Steven K; Andersen C; Hald T; Zeuthen J
Cancer Res; 1992 Feb; 52(3):726-33. PubMed ID: 1732060
[TBL] [Abstract][Full Text] [Related]
18. Assay of lymphokine-activated killer activity generated from bone marrow cells of children with acute lymphoblastic leukemia.
Zhou MX; Findley HW; Davis R; Ragab AH
Blood; 1990 Jan; 75(1):160-5. PubMed ID: 2294987
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloblastic leukaemia: graft-versus-host and graft-versus-leukaemia responses to autologous IL-2 activated lymphocytes in rapid and slow disease.
Boughton BJ; Simpson AW
Cytokines Cell Mol Ther; 1999 Mar; 5(1):1-6. PubMed ID: 10390074
[TBL] [Abstract][Full Text] [Related]
20. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
